Evropska unija - slovenščina - EMA (European Medicines Agency)

ultragenyx germany gmbh - evinacumab - hiperholesterolemija - sredstva za spreminjanje lipidov - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).

Evropska unija - slovenščina - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - imunosupresivi - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Evropska unija - slovenščina - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - imunski sera in imunoglobulini, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

dechra regulatory -

Evropska unija - slovenščina - EMA (European Medicines Agency)

amicus therapeutics europe limited - cipaglucosidase alfa - bolezen tipa ii za shranjevanje glikogena - drugi zdravljene bolezni prebavil in presnove izdelki, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).